Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis
– Trial did not meet the primary endpoint of annualized rate of FVC decline –
– Trial did not meet the primary endpoint of annualized rate of FVC decline –